首页> 外文期刊>Clinical ophthalmology >Adjunctive intravitreal dexamethasone in the treatment of acute endophthalmitis following cataract surgery
【24h】

Adjunctive intravitreal dexamethasone in the treatment of acute endophthalmitis following cataract surgery

机译:玻璃体腔内地塞米松辅助治疗白内障术后急性眼内炎

获取原文
       

摘要

Purpose: Controversy exists regarding the use of intravitreal dexamethasone (IVD) as an anti-inflammatory adjunct to intravitreal antibiotics in patients with acute endophthalmitis following cataract surgery. The purpose of this project was to evaluate our experience regarding the effect of adjunctive IVD use on visual outcomes in such patients.Design: Retrospective, comparative case series.Methods: Study population: Patients treated for acute endophthalmitis following cataract surgery from 1995–2004. Intervention: In addition to standard intravitreal antibiotic treatment, some patients also received a single adjunctive injection of IVD. Primary outcome measures: Median visual acuity at last follow-up and percentage of patients achieving a ≥3-line improvement in visual acuity. Secondary outcome measures: Inflammatory index scoring, including amount of cell and flare, height of hypopyon, and presence of fibrin as a function of time after treatment.Results: Twenty-six eyes were treated with and 38 eyes without adjunctive IVD. Median presenting visual acuity was Hand Motion in both groups. Median visual acuity at last followup measured 20/40 in the IVD group and 20/50 in the No-IVD group (p = 0.75). Seventy-three percent of patients in the IVD group and 82% of patients in the No-IVD group achieved a ≥3-line improvement in visual acuity (p = 0.42). No significant difference was detected between the IVD and No-IVD groups for any of the three measures of inflammation.Conclusion: The use of IVD did not significantly improve the final median visual acuity, the chance of achieving a ≥3-line improvement in visual acuity, or the amount of intraocular inflammation. Based on these findings, and the possible detrimental effect of IVD on visual outcomes previously reported in the literature, the use of IVD does not appear to be warranted as a routine adjunctive treatment in postoperative endophthalmitis.
机译:目的:对于白内障手术后急性眼内炎患者使用玻璃体内地塞米松(IVD)作为玻璃体内抗生素的消炎辅助剂存在争议。本项目的目的是评估我们在此类患者中使用辅助IVD对视力结果的影响的经验。设计:回顾性,比较病例系列。方法:研究人群:1995年至2004年白内障手术后接受过急性眼内炎治疗的患者。干预:除了标准的玻璃体内抗生素治疗外,一些患者还接受了单次IVD辅助注射。主要结局指标:末次随访时的中位视敏度和获得≥3级视力改善的患者百分比。次要结果指标:炎性指数评分,包括细胞数量和耀斑数量,hyperpyon的高度和纤维蛋白的存在与治疗后时间的关系。结果:26眼接受了IVD治疗,38眼没有进行辅助性IVD。两组中呈现视觉敏锐度的中位数为手运动。 IVD组最后一次随访的中位视力为20/40,No-IVD组为20/50(p = 0.75)。 IVD组的73%的患者和No-IVD组的82%的患者的视力提高了≥3行(p = 0.42)。 IVD组和No-IVD组在三种炎症指标中均未发现显着差异。结论:使用IVD并不能显着改善最终中位视敏度,获得≥3行视力改善的机会敏锐度或眼内炎症的量。基于这些发现,以及先前文献中报道的IVD对视觉结果的可能有害影响,似乎不应该肯定IVD在术后眼内炎中作为常规辅助治疗的必要性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号